313548-32-2

Upstream product

• 29799-07-3 4-adamantylphenol 
• 52804-25-8 (4-adamantyl-1-yl-phenoxy) acetic acid ethyl ester 
• 52804-26-9 (4-adamantan-1-yl-phenoxy)acetic acid 
• 619-45-4 4-methoxycarbonyl aniline 

Relevant academic research and scientific papers

COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT

Disclosed herein are an HIF-1 inhibitor, a method for the preparation thereof, and a pharmaceutical composition comprising the same as an active ingredient. The HIF-1 inhibitor shows anticancer activity thanks to the inhibition activity against HIF-1, a transcription factor which plays an important role in the growth and metastasis of cancer, but not to general cytotoxicity. Thus, the HIF-inhibitor and a pharmaceutically acceptable salt thereof can be used as a therapeutic for various cancers such as liver cancer; stomach cancer and breast cancer. Also, the compound having inhibition activity against HIF-1 is useful in the treatment of diabetic retinopathy and arthritis, which are aggravated by HIF-1-mediated VEGF expression.

COMPOUNDS TEAT INHIBIT HBF-I ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT

Disclosed herein are an HIF-I inhibitor, a method for the preparation thereof, and a pharmaceutical composition comprising the same as an active ingredient The BDDF-I inhibitor shows anticancer activity thanks to the inhibition activity against HIF-I, a transcription factor which plays an important role in the growth and metastasis of cancer, but not to general cytotoxicity. Thus, the HIF-inhibitor and a pharmaceutically acceptable salt thereof can be used as a therapeutic for various cancers such as liver cancer, stomach cancer and breast cancer. Also, the compound having inhibition activity against HDDF-I is useful in the treatment of diabetic retinopathy and arthritis, which are aggravated by HEF-l-mediated VEGF expression.

(Aryloxyacetylamino)benzoic acid analogues: A new class of hypoxia-inducible factor-1 inhibitors

Structural modification of a compound discovered during screening using an HRE-dependent reporter assay has revealed a novel class of HIF-1 inhibitors, which potently inhibit the HIF-1α protein accumulation and its target gene expression under hypoxic conditions in human hepatocellular carcinoma Hep3B cells.